The type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-modifying therapies in clinical trials pose challenges to market growth.
Related tickers: NVO, LLY, SNY, AZN, LXRX, FUJIY, NVS, MRK, ALPMY, AMGN, VTVT, BMY, CELGr, ADOCY, JNJ.
Read Full Article
